Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...